gypenoside-LXXV has been researched along with Cognitive-Dysfunction* in 2 studies
2 other study(ies) available for gypenoside-LXXV and Cognitive-Dysfunction
Article | Year |
---|---|
Increasing brain glucose uptake by Gypenoside LXXV ameliorates cognitive deficits in a mouse model of diabetic Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus; Disease Models, Animal; Glucose; Mice; Mice, Transgenic; Phosphatidylinositol 3-Kinases; PPAR gamma; Proto-Oncogene Proteins c-akt | 2023 |
A novel natural PPARĪ³ agonist, Gypenoside LXXV, ameliorates cognitive deficits by enhancing brain glucose uptake via the activation of Akt/GLUT4 signaling in db/db mice.
Topics: Animals; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Glucose; Glucose Transporter Type 4; Gynostemma; Insulin; Insulin Resistance; Mice; PPAR gamma; Proto-Oncogene Proteins c-akt; Saponins; Triterpenes | 2022 |